Cargando…

Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study

OBJECTIVE: The use of adjuvant endocrine therapy (AET) after primary treatment of hormone receptor‐positive breast cancer reduces the risk of recurrence and mortality. However, non‐adherence is still common. Limited consideration has been given to how users deal with AET and the role of pharmaceutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	En‐nasery ‐ de Heer, Selma, Tromp, Vashti N. M. F., Westerman, Marjan J., Konings, Inge, Beckeringh, Jan Jacob, Boons, Christel L. M., Timmers, Lonneke, Hugtenburg, Jacqueline G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786726/ https://www.ncbi.nlm.nih.gov/pubmed/36300863 http://dx.doi.org/10.1111/ecc.13749

Ejemplares similares

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia
por: Boons, Christel CLM, et al.
Publicado: (2014)

The use of erlotinib in daily practice: a study on adherence and patients' experiences
por: Timmers, Lonneke, et al.
Publicado: (2011)

Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists
por: Timmers, Lonneke, et al.
Publicado: (2017)

The use of capecitabine in daily practice: a study on adherence and patients’ experiences
por: Timmers, Lonneke, et al.
Publicado: (2012)

Implementation of a pharmacist‐led transitional pharmaceutical care programme: Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH)
por: En‐nasery‐de Heer, Selma, et al.
Publicado: (2022)

Patient satisfaction with information on oral anticancer agent use
por: Boons, Christel C. L. M., et al.
Publicado: (2017)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
por: Hugtenburg, Jacqueline G, et al.
Publicado: (2013)

Barriers and Enablers of Healthcare Providers to Deprescribe Cardiometabolic Medication in Older Patients: A Focus Group Study
por: Abou, Jamila, et al.
Publicado: (2022)

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice
por: Timmers, Lonneke, et al.
Publicado: (2016)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Factors Associated With Nonadherence to Cardiovascular Medications: A Cross-sectional Study
por: van der Laan, Danielle M., et al.
Publicado: (2019)

The impact of cardiovascular medication use on patients’ daily lives: a cross-sectional study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial
por: van der Laan, Danielle M., et al.
Publicado: (2017)

Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies
por: van der Laan, Danielle M., et al.
Publicado: (2019)

The Cost-Effectiveness of an Intervention Program to Enhance Adherence to Antihypertensive Medication in Comparison With Usual Care in Community Pharmacies
por: Bosmans, Judith E., et al.
Publicado: (2019)

Factors related to high and low levels of drug adherence according to patients with type 2 diabetes
por: Borgsteede, Sander D., et al.
Publicado: (2011)

Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015)

Manufacturers’ views on outcome-based agreements
por: Barjestehvan Waalwijk van Doorn-Khosrovani, Sahar, et al.
Publicado: (2021)

SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial
por: Billingy, Nicole E, et al.
Publicado: (2021)

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

Pharmaceutical Point of View on Parenteral Nutrition
por: Stawny, M., et al.
Publicado: (2013)

Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy
por: Tan, Eng Hooi, et al.
Publicado: (2021)

Vitamin D and Neurological Diseases: An Endocrine View
por: Di Somma, Carolina, et al.
Publicado: (2017)

Completion of 5-year adjuvant endocrine therapy in the community
por: Makubate, B, et al.
Publicado: (2010)

An unmet need: tailoring extended adjuvant endocrine therapy
por: Bianchini, G, et al.
Publicado: (2013)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Impact of endocrine disrupting chemicals and pharmaceuticals on Sertoli cell development and functions
por: Corpuz-Hilsabeck, Maia, et al.
Publicado: (2023)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

The evolution of insect metamorphosis: a developmental and endocrine view
por: Truman, James W., et al.
Publicado: (2019)

Adjuvant endocrine therapy for premenopausal women with early breast cancer
por: Bao, Ting, et al.
Publicado: (2007)

Breast density predicts endocrine treatment outcome in the adjuvant setting
por: Cuzick, Jack
Publicado: (2012)

Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
por: Lambert, Leah K., et al.
Publicado: (2018)

Aquatic Insects Transfer Pharmaceuticals and Endocrine Disruptors from Aquatic to Terrestrial Ecosystems
por: Previšić, Ana, et al.
Publicado: (2021)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
por: Hara, Fumikata, et al.
Publicado: (2010)

Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
por: Lee, Joo Yun, et al.
Publicado: (2018)

Optimal duration of adjuvant endocrine therapy: how to apply the newest data
por: Wimmer, Kerstin, et al.
Publicado: (2017)

Management of diabetic foot ulcers and the challenging points: An endocrine view
por: Doğruel, Hakan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bp599o140nqsoejvjdkag9b61d